Vein of Marshall Ethanol Infusion for AF Ablation; A Review.
Louisa O'NeillBenjamin De BeckerMaarten De SmetClara FrancoisRene TavernierMattias DuytschaeverJean-Benoit Le Polain De WarouxSebastien KnechtPublished in: Journal of clinical medicine (2024)
The outcomes of persistent atrial fibrillation (AF) ablation are modest with various adjunctive strategies beyond pulmonary vein isolation (PVI) yielding largely disappointing results in randomised controlled trials. Linear ablation is a commonly employed adjunct strategy but is limited by difficulty in achieving durable bidirectional block, particularly at the mitral isthmus. Epicardial connections play a role in AF initiation and perpetuation. The ligament of Marshall has been implicated as a source of AF triggers and is known to harbour sympathetic and parasympathetic nerve fibres that contribute to AF perpetuation. Ethanol infusion into the Vein of Marshall, a remnant of the superior vena cava and key component of the ligament of Marshall, may eliminate these AF triggers and can facilitate the ease of obtaining durable mitral isthmus block. While early trials have demonstrated the potential of Vein of Marshall 'ethanolisation' to reduce arrhythmia recurrence after persistent AF ablation, further randomised trials are needed to fully determine the potential long-term outcome benefits afforded by this technique.
Keyphrases
- atrial fibrillation
- catheter ablation
- left atrial
- oral anticoagulants
- left atrial appendage
- direct oral anticoagulants
- vena cava
- mitral valve
- heart failure
- percutaneous coronary intervention
- left ventricular
- clinical trial
- low dose
- radiofrequency ablation
- open label
- randomized controlled trial
- double blind
- coronary artery disease
- inferior vena cava
- pulmonary embolism
- heart rate
- skeletal muscle